Antenatal Dexamethasone Treatment Leads to Changes in Gene Expression in a Murine Late Placenta

Placenta

Volumn 28, Issue 10, 2007, Pages 1082-1090

  Baisden, B ^a   Sonne, S ^a   Joshi, R M ^a   Ganapathy, V ^a   Shekhawat, P S ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antenatal steroids; Dexamethasone; Fetal growth; Microarrays; Placental gene expression

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; AQUAPORIN 5; BONE MORPHOGENETIC PROTEIN 4; COLONY STIMULATING FACTOR 1; COMPLEMENT COMPONENT C3; CYCLIN A2; CYCLIN B1; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN F; CYCLINE; CYTOKERATIN 14; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; FATTY ACID TRANSPORTER; FATTY ACID TRANSPORTER 6; M PHASE PROTEIN KINASE; MATRILYSIN; PROTEIN KINASE; SODIUM CHLORIDE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; THYROTROPIN RECEPTOR; TRYPTOPHAN HYDROXYLASE; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIVISION; CONTROLLED STUDY; FEMALE; FETUS; FETUS DISEASE; FETUS GROWTH; FETUS HYDROPS; FETUS WEIGHT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLACENTA FUNCTION; PLACENTA WEIGHT; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TROPHOBLAST; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; AQUAPORIN 5; CASPASE 1; CASPASE 3; DEXAMETHASONE; DOWN-REGULATION; FEMALE; FETAL GROWTH RETARDATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLACENTA; PREGNANCY; TRYPTOPHAN HYDROXYLASE; UP-REGULATION;

EID: 34548412178     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2007.04.002     Document Type: Article

References (52)

1. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev (2000) CD000065
2. Committee on Obstetric P. ACOG committee opinion: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 99 (2002) 871-873
3. Moise A.A., Wearden M.E., Kozinetz C.A., Gest A.L., Welty S.E., and Hansen T.N. Antenatal steroids are associated with less need for blood pressure support in extremely premature infants. Pediatrics 95 (1995) 845-850
4. Doyle L.W., Ford G.W., Rickards A.L., Kelly E.A., Davis N.M., Callanan C., et al. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. Pediatrics 106 (2000) E2
5. Schaap A.H., Wolf H., Bruinse H.W., Smolders-De Haas H., Van Ertbruggen I., and Treffers P.E. Effects of antenatal corticosteroid administration on mortality and long-term morbidity in early preterm, growth-restricted infants. Obstet Gynecol 97 (2001) 954-960
6. Thorp J.A., Jones A.M., Hunt C., and Clark R. The effect of multidose antenatal betamethasone on maternal and infant outcomes. Am J Obstet Gynecol 184 (2001) 196-202
7. Walfisch A., Hallak M., and Mazor M. Multiple courses of antenatal steroids: risks and benefits. Obstet Gynecol 98 (2001) 491-497
8. Newnham J.P., and Moss T.J. Antenatal glucocorticoids and growth: single versus multiple doses in animal and human studies. Semin Neonatol 6 (2001) 285-292
9. Lee M.J., Davies J., Guinn D., Sullivan L., Atkinson M.W., McGregor S., et al. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes. Obstet Gynecol 103 (2004) 274-281
10. Thorp J.A., Jones P.G., Knox E., and Clark R.H. Does antenatal corticosteroid therapy affect birth weight and head circumference?. Obstet Gynecol 99 (2002) 101-108
11. Spinillo A., Viazzo F., Colleoni R., Chiara A., Maria Cerbo R., et al. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 191 (2004) 217-224
12. O'Regan D., Kenyon C.J., Seckl J.R., and Holmes M.C. Glucocorticoid exposure in late gestation in the rat permanently programs gender-specific differences in adult cardiovascular and metabolic physiology. Am J Physiol Endocrinol Metab 287 (2004) E863-E870
13. Benediktsson R., Calder A.A., Edwards C.R., and Seckl J.R. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin Endocrinol (Oxf) 46 (1997) 161-166
14. Michael A.E., Thurston L.M., and Rae M.T. Glucocorticoid metabolism and reproduction: a tale of two enzymes. Reproduction 126 (2003) 425-441
15. Diederich S., Eigendorff E., Burkhardt P., Quinkler M., Bumke-Vogt C., Rochel M., et al. 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 87 (2002) 5695-5701
16. Stewart P.M., Rogerson F.M., and Mason J.I. Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab 80 (1995) 885-890
17. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 25 (2004) 831-866
18. Dave-Sharma S., Wilson R.C., Harbison M.D., Newfield R., Azar M.R., Krozowski Z.S., et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 83 (1998) 2244-2254
19. Kallen C.B. Steroid hormone synthesis in pregnancy. Obstet Gynecol Clin North Am 31 (2004) 795-816
20. Ain R., Canham L.N., and Soares M.J. Dexamethasone-induced intrauterine growth restriction impacts the placental prolactin family, insulin-like growth factor-II and the Akt signaling pathway. J Endocrinol 185 (2005) 253-263
21. Murphy V.E., Fittock R.J., Zarzycki P.K., Delahunty M.M., Smith R., and Clifton V.L. Metabolism of synthetic steroids by the human placenta. Placenta 28 (2007) 39-46
22. Waddell B.J., Hisheh S., Dharmarajan A.M., and Burton P.J. Apoptosis in rat placenta is zone-dependent and stimulated by glucocorticoids. Biol Reprod 63 (2000) 1913-1917
23. Newnham J.P., Evans S.F., Godfrey M., Huang W., Ikegami M., and Jobe A. Maternal, but not fetal, administration of corticosteroids restricts fetal growth. J Matern Fetal Med 8 (1999) 81-87
24. Allison D.B., Cui X., Page G.P., and Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7 (2006) 55-65
25. de Kok J.B., Roelofs R.W., Giesendorf B.A., Pennings J.L., Waas E.T., Feuth T., et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab Invest 85 (2005) 154-159
26. Srinivas S.R., Gopal E., Zhuang L., Itagaki S., Martin P.M., Fei Y.J., et al. Cloning and functional identification of slc5a12 as a sodium-coupled low-affinity transporter for monocarboxylates (SMCT2). Biochem J 392 (2005) 655-664
27. Crowley P. Antenatal corticosteroids-current thinking. Bjog 110 Suppl. 20 (2003) 77-78
28. Leung T.N., Lam P.M., Ng P.C., and Lau T.K. Repeated courses of antenatal corticosteroids: is it justified?. Acta Obstet Gynecol Scand 82 (2003) 589-596
29. Newnham J.P., Moss T.J., Nitsos I., and Sloboda D.M. Antenatal corticosteroids: the good, the bad and the unknown. Curr Opin Obstet Gynecol 14 (2002) 607-612
30. Doyle L.W., Kitchen W.H., Ford G.W., Rickards A.L., Lissenden J.V., and Ryan M.M. Effects of antenatal steroid therapy on mortality and morbidity in very low birth weight infants. J Pediatr 108 (1986) 287-292
31. Arad I., Durkin M.S., Hinton V.J., Kuhn L., Chiriboga C., Kuban K., et al. Long-term cognitive benefits of antenatal corticosteroids for prematurely born children with cranial ultrasound abnormalities. Am J Obstet Gynecol 186 (2002) 818-825
32. Kutzler M.A., Ruane E.K., Coksaygan T., Vincent S.E., and Nathanielsz P.W. Effects of three courses of maternally administered dexamethasone at 0.7, 0.75, and 0.8 of gestation on prenatal and postnatal growth in sheep. Pediatrics 113 (2004) 313-319
33. Coe C.L., and Lubach G.R. Developmental consequences of antenatal dexamethasone treatment in nonhuman primates. Neurosci Biobehav Rev 29 (2005) 227-235
34. Uno H., Eisele S., Sakai A., Shelton S., Baker E., DeJesus O., et al. Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 28 (1994) 336-348
35. Bloom S.L., Sheffield J.S., McIntire D.D., and Leveno K.J. Antenatal dexamethasone and decreased birth weight. Obstet Gynecol 97 (2001) 485-490
36. Seckl J.R. Prenatal glucocorticoids and long-term programming. Eur J Endocrinol 151 Suppl. 3 (2004) U49-U62
37. Georgiades P., Ferguson-Smith A.C., and Burton G.J. Comparative developmental anatomy of the murine and human definitive placentae. Placenta 23 (2002) 3-19
38. Blanford A.T., and Murphy B.E. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 127 (1977) 264-267
39. Wilson R.C., Dave-Sharma S., Wei J.Q., Obeyesekere V.R., Li K., Ferrari P., et al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci U S A 95 (1998) 10200-10205
40. Ugrasbul F., Wiens T., Rubinstein P., New M.I., and Wilson R.C. Prevalence of mild apparent mineralocorticoid excess in Mennonites. J Clin Endocrinol Metab 84 (1999) 4735-4738
41. Losel R., and Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4 (2003) 46-56
42. Murray A.W. Recycling the cell cycle: cyclins revisited. Cell 116 (2004) 221-234
43. Musgrove E.A. Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors 24 (2006) 13-19
44. Baserga M., Hale M.A., McKnight R.A., Yu X., Callaway C.W., and Lane R.H. Uteroplacental insufficiency alters hepatic expression, phosphorylation, and activity of the glucocorticoid receptor in fetal IUGR rats. Am J Physiol Regul Integr Comp Physiol 289 (2005) R1348-R1353
45. Tetzlaff M.T., Bai C., Finegold M., Wilson J., Harper J.W., Mahon K.A., et al. Cyclin F disruption compromises placental development and affects normal cell cycle execution. Mol Cell Biol 24 (2004) 2487-2498
46. Straszewski-Chavez S.L., Abrahams V.M., and Mor G. The role of apoptosis in the regulation of trophoblast survival and differentiation during pregnancy. Endocr Rev 26 (2005) 877-897
47. Zhou Y., Wang Q., Evers B.M., and Chung D.H. Signal transduction pathways involved in oxidative stress-induced intestinal epithelial cell apoptosis. Pediatr Res 58 (2005) 1192-1197
48. Langdown M.L., Holness M.J., and Sugden M.C. Early growth retardation induced by excessive exposure to glucocorticoids in utero selectively increases cardiac GLUT1 protein expression and Akt/protein kinase B activity in adulthood. J Endocrinol 169 (2001) 11-22
49. Song Y., and Verkman A.S. Aquaporin-5 dependent fluid secretion in airway submucosal glands. J Biol Chem 276 (2001) 41288-41292
50. Watts S.W. 5-HT in systemic hypertension: foe, friend or fantasy?. Clin Sci (Lond) 108 (2005) 399-412
51. Morrison J.L., Riggs K.W., and Rurak D.W. Fluoxetine during pregnancy: impact on fetal development. Reprod Fertil Dev 17 (2005) 641-650
52. Nyirenda M.J., Dean S., Lyons V., Chapman K.E., and Seckl J.R. Prenatal programming of hepatocyte nuclear factor 4alpha in the rat: a key mechanism in the 'fetal origins of hyperglycaemia'?. Diabetologia 49 (2006) 1412-1420